National Bank of Canada FI Has $22.59 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• National Bank of Canada FI increased its stake in IQVIA Holdings Inc. by 55.0%, acquiring an additional 45,490 shares during the first quarter, raising their total ownership to 128,158 shares valued at approximately $22.6 million.
• Other institutional investors, including Pacer Advisors Inc. and Canada Pension Plan Investment Board, significantly increased their holdings in IQVIA, demonstrating strong institutional interest in the company.
• IQVIA reported a quarterly EPS of $2.81, surpassing estimates, with revenues of $4.02 billion, a year-over-year increase of 5.3%, indicating robust financial performance amidst varying analyst ratings.

National Bank of Canada FI grew its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 55.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 128,158 shares of the medical research company's stock after buying an additional 45,490 shares during the period. National Bank of Canada FI owned approximately 0.07% of IQVIA worth $22,594,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in IQV. Pacer Advisors Inc. lifted its position in shares of IQVIA by 5,036.1% in the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock worth $153,681,000 after buying an additional 854,732 shares during the last quarter. Canada Pension Plan Investment Board lifted its position in shares of IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after purchasing an additional 712,958 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its position in shares of IQVIA by 211.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 965,302 shares of the medical research company's stock worth $189,691,000 after purchasing an additional 655,153 shares during the last quarter. Marshall Wace LLP lifted its position in shares of IQVIA by 85.4% during the 4th quarter. Marshall Wace LLP now owns 954,294 shares of the medical research company's stock worth $187,528,000 after purchasing an additional 439,649 shares during the last quarter. Finally, Cadian Capital Management LP acquired a new position in shares of IQVIA during the 4th quarter worth about $78,604,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 5,800 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

IQVIA Price Performance

NYSE IQV traded down $0.73 during trading hours on Thursday, reaching $189.50. 637,769 shares of the company's stock were exchanged, compared to its average volume of 1,992,763. The stock has a market cap of $32.21 billion, a PE ratio of 27.42, a price-to-earnings-growth ratio of 2.04 and a beta of 1.30. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The firm has a fifty day moving average of $168.77 and a 200-day moving average of $169.04. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. IQVIA's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.64 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the subject of several research analyst reports. JPMorgan Chase & Co. cut their price objective on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Truist Financial boosted their price objective on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. William Blair reissued an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. HSBC cut IQVIA from a "buy" rating to a "hold" rating and cut their price objective for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. Finally, Cowen reissued a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Seven analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $228.62.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.